Real-World Evidence Services
Achieve your oncology real-world evidence goals faster and more efficiently
Accelerate development timelines, optimize evidence needs, and build the value story with analytics, regulatory, and consulting services from Flatiron.
Our in-house expertise is what sets us apart
Flatiron provides tailored oncology evidence solutions for every phase of the biopharma lifecycle.
While every research question has its unique nuances that require deeper understanding, our experts frequently support the following areas of research:
-
Natural history studies and studies of unmet need
-
Comparative effectiveness research, including external control arms
-
Protocol optimization studies to improve inclusion of underrepresented populations
-
Patient recruitment and site selection strategies to power clinical trial study designs and predict study timelines
-
Reports to monitor uptake for newly approved assets and describe market share
-
Assessments of transportability
-
Real-world assessments of dosing patterns and drug safety
-
Strategic support in interactions with regulators and briefing book development
12+
years exclusively in oncology
5+
years of direct collaboration with FDA
350+
custom data and services projects delivered
50+
submissions to regulatory authorities and HTA bodies
500+
publications featuring Flatiron Data
90+
publications co-authored with customers
RWE services, powered by Flatiron Horizon
Multi-disciplinary approach and expertise
Our services teams comprise of research oncologists, biostatisticians, epidemiologists, and regulatory specialists – skilled at applying RWE across the oncology drug lifecycle.
Researchers with data empathy
Flatiron has over a decade of experience at the forefront of RWE innovation. That’s why our scientists have deep data empathy, a multi-faceted understanding of oncology RWE and its use.
Flexible and cost-effective contracting options
Allows life sciences companies to choose a solution that best fits their needs and budget.
Integrated at the source
Our services leverage data from our electronic health record system, OncoEMR, integrated at the point-of-care, offering unmatched scale, clinical depth, and quality.
Published with partners
With a record of advancing RWE research, Flatiron has collaborated with partners like the FDA, NCCN, and NICE to advance endpoint validation methods.
Flexible engagement models for dynamic needs
We understand that each use case is unique, as are the needs of our partners. Flatiron offers a variety of ways to engage with our teams, spanning end-to-end RWE research and evidence generation to quick analytical insights. Here are a few examples of ways we’ve partnered with our clients.
examples include:
End-to-end real-world evidence support
Our expert team can provide support from study design and protocol design and optimization to analysis and publication. We can lead and execute scientific research projects, ensuring accurate and timely delivery of results.
Insights delivered on a regular cadence
With specialized skills and knowledge in oncology RWE, Flatiron can provide ongoing analytical support including information on treatment patterns, treatment outcomes, patient persistence, and more.
One-time insights for a specific research or business question
For rapid answers to critical questions, our team can generate actionable insights quickly to inform decision-making.
We can also work with you to craft a custom solution that meets your needs.
Success Stories
Analytic insights driving faster and more confident decisions
Flatiron provided crucial ongoing RWE analytic support to a health economics and outcomes research team (HEOR) at a top biopharma company, answering key business questions spanning post-market strategy, trial design, and outcomes evaluation. This critical support helped the client optimize its RWD subscription, increasing their internal knowledge of working with Flatiron data.
Comparative effectiveness study in metastatic colorectal cancer to support HTA decision-making
“Flatiron’s seamless collaborative approach and subject matter knowledge advanced a real-world comparative effectiveness study evaluating treatment-specific sub-cohorts within a broader, real-world biomarker-identified population. Flatiron’s scientific innovation and breadth of analytic capabilities have greatly contributed to generating impactful evidence for this oncology research project.”
— Customer Testimonial, WW HEOR Director of Life Science Company
Unmet medical need evaluation to informoncology portfolio strategy
Flatiron’s RWE study helped a biopharma executive team prioritize R&D investment, deciding which early stage assets in five therapeutic areas to pursue. The Flatiron study established unmet need by evaluating real-world survival outcomes in a treatment- specific cohort with advanced urothelial carcinoma (aUC) who had disease relapse.
Get started today
Contact us now to learn more about our flexible, tailored solutions and how we can support your oncology evidence generation needs.